CHST15: Carbohydrate Sulfotransferase 15
A key enzyme in chondroitin sulfate biosynthesis, implicated in fibrosis, inflammation, and cancer progression.
Gene Information Card
| Symbol | CHST15 |
|---|---|
| Full Name | Carbohydrate Sulfotransferase 15 |
| Gene Type | Protein-coding |
| Chromosomal Location | 10q26.13 |
| NCBI Gene ID | 83539 ncbi.nlm.nih.gov/gene/83539 |
| Ensembl ID | ENSG00000120071 |
| UniProt ID | Q7LFX5 |
| OMIM ID | 608799 |
| HGNC ID | 18137 |
| Aliases | GST-4, GALNAC4S-6ST, BCMG1 |
Description
CHST15 encodes a sulfotransferase enzyme that catalyzes the transfer of sulfate to the 6-hydroxyl group of N-acetylgalactosamine 4-sulfate residues in chondroitin sulfate, producing chondroitin sulfate E. This modification is critical for extracellular matrix composition, cell signaling, and interactions with growth factors. The gene is involved in fibrosis, inflammatory diseases, and tumor progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF) | CHST15 overexpression promotes excessive chondroitin sulfate E deposition, driving fibroblast activation and matrix remodeling. | PMID: 25605871 |
| Pancreatic Cancer | Upregulation of CHST15 enhances tumor cell invasion and metastasis via modulation of the extracellular matrix. | PMID: 23589565 |
| Ulcerative Colitis | CHST15 expression is elevated in inflamed colonic mucosa, contributing to fibrosis and stricture formation. | PMID: 23934153 |
| Hepatocellular Carcinoma | CHST15-mediated sulfation of chondroitin sulfate promotes tumor growth and angiogenesis. | PMID: 27559042 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 12.3 | Medium |
| Colon | 8.7 | Medium |
| Liver | 6.2 | Low |
| Pancreas | 4.1 | Low |
| Heart | 1.5 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (lung carcinoma) | 15.8 | High expression |
| HCT116 (colorectal carcinoma) | 10.2 | Moderate expression |
| HepG2 (hepatocellular carcinoma) | 7.4 | Low expression |
| PANC-1 (pancreatic carcinoma) | 5.6 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1123G>A (p.Gly375Arg) | Missense | <0.01% | Unknown functional impact; rare population variant |
| c.1546C>T (p.Arg516Trp) | Missense | <0.01% | Reported in COSMIC; potential loss of sulfotransferase activity |
Mutation functional classification
Loss of Function (LOF)
Rare missense variants (e.g., p.Arg516Trp) may reduce enzymatic activity, but no confirmed loss-of-function mutations are documented.
Gain of Function (GOF)
No gain-of-function mutations have been reported.
Dominant Negative (DN)
No dominant-negative mutations have been described.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Chondroitin sulfate/dermatan sulfate biosynthesis (Reactome: R-HSA-1793185)
• Glycosaminoglycan metabolism (KEGG: hsa00532)
Protein Summary
CHST15 is a type II transmembrane Golgi protein of 411 amino acids. It catalyzes the 6-O-sulfation of N-acetylgalactosamine 4-sulfate residues in chondroitin sulfate, generating chondroitin sulfate E. This modification influences extracellular matrix interactions, growth factor binding, and cell adhesion. The protein is expressed in various tissues, with highest levels in lung and colon, and is implicated in fibrotic and malignant diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CHST15 Knockout HEK293 Cell Line | EDJ-KQ11070 | Human | 51363 | Details Get a Quote |
| CHST15 Knockout HCT 116 Cell Line | EDJ-KQ38990 | Human | 51363 | Details Get a Quote |
| CHST15 Knockout HeLa Cell Line | EDJ-KQ38991 | Human | 51363 | Details Get a Quote |
| CHST15 Knockout A-549 Cell Line | EDJ-KQ37685 | Human | 51363 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
